Next Article in Journal
Synthesis and Anticonvulsant Activity of Certain N-Aralkyl-N-(1-Substituted Cyclohexyl) Benzenamines
Previous Article in Journal
Rosiglitazone modifies PEDF gene expression and protein levels in the Koletsky rat choroid-RPE complex
Article Menu

Article Versions

Export Article

Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Articles in this Issue were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence. Articles are hosted by MDPI on as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
Open AccessArticle
Sci. Pharm. 2008, 76(2), 151-170; (registering DOI)

Preparation, Quality Control and Biodistribution Studies of two [111In]-Rituximab Immunoconjugates

Nuclear Medicine Research Group, Agricultural, Medical and Industrial Research School (AMIRS), P.O.Box: 31485-498, Karaj, Iran
Islamic Azad University, Science and Research Unit, P.O.Box: 14155-775, Tehran, Iran
Author to whom correspondence should be addressed.
Received: 6 April 2008 / Accepted: 15 May 2008 / Published: 18 May 2008
PDF [386 KB, uploaded 27 December 2016]


In order to use Auger-electron therapeutic effects in CD20 antigen targeting in lymphomas, Mabthera™ (rituximab) was successively labeled with [111In]-indium chloride (185 MBq) after conjugation with freshly prepared macrocyclic bifunctional chelating agent, N-succinimidyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA-NHS) and ccDTPA separately. Conjugated-Rituximab was obtained by the addition of 1 ml of a rituximab pharmaceutical solution (5 mg/ml, in phosphate buffer, pH=7.8) to a glass tube pre-coated with freshly prepared DOTA-NHS or ccDTPA (0.01-0.1 mg) at 25°C. Radiolabeling was performed at 37°C in 3h and room temperature for one hour for DOTA-conjugate and DTPA-conjugate respectively. HPLC showed an overall radiochemical purity of 97.5 and 95% for DOTA and DTPA-conjugates respectively (Specific activity =2800-5600 GBq/mM). The final isotonic 111In-rituximab complexes were checked by gel electrophoresis for radiolysis. Preliminary biodistribution studies in normal rat model performed to determine radioimmunoconjugates distribution of up to 48h.
Keywords: Rituximab; Indium-111; Biodistribution; Radiolabeling; Targetted Therapy Rituximab; Indium-111; Biodistribution; Radiolabeling; Targetted Therapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

JALILIAN, A.R.; SARDARI, D.; KIA, L.; ROWSHANFARZAD, P.; GAROUSI, J.; AKHLAGHI, M.; SHANEHSAZZADEH, S.; MIRZAII, M. Preparation, Quality Control and Biodistribution Studies of two [111In]-Rituximab Immunoconjugates. Sci. Pharm. 2008, 76, 151-170.

Show more citation formats Show less citations formats

Article Metrics

Article Access Statistics



[Return to top]
Sci. Pharm. EISSN 2218-0532 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top